[18F]FDG PET/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis
Our findings underscore the superiority of PET against CT in therapy monitoring of RPF, especially in the detection of progression at FU2. Higher BL MAV correlated with progression at FU2, indicating its potential as a predictive marker. Still, especially when PET is not available, CT can be considered for initial therapy monitoring.
Authors
- Christian Bayerl (ORCID: https://orcid.org/0000-0001-7107-3934)
- Jonas Kaufmann (ORCID: https://orcid.org/0000-0002-4487-9665)
- Markus van der Giet (ORCID: https://orcid.org/0000-0003-3590-5451)
- Julian M.M. Rogasch (ORCID: https://orcid.org/0000-0002-0817-6532)
- Holger Amthauer (ORCID: https://orcid.org/0000-0003-4414-0657)
- Imke Schatka (ORCID: https://orcid.org/0000-0002-2628-6145)
- Christian Furth (ORCID: https://orcid.org/0000-0001-7302-7886)
- Winfried Brenner (ORCID: https://orcid.org/0000-0003-2478-6004)
- Giulia Metzger (ORCID: https://orcid.org/0009-0003-2399-2364)
Institutions
- Humboldt-Universität zu Berlin (DE)
- German Cancer Society (DE)
- National Center for Tumor Diseases (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1007/s00259-025-07479-6
- Primary Topic
- IgG4-Related and Inflammatory Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Charité – Universitätsmedizin Berlin